Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.
lupus
Researchers Identify Lupus Trigger
Researchers identified three proteins, called Toll-Like Receptors (TLRs), that can cause the immune system to turn against the body.
Positive Results for Human Genome’s Lupus Drug Benlysta
Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.